April 10, 2020 -- Enzychem Lifesciences has filed a provisional patent application with the U.S. Patent and Trademark Office to cover treating COVID-19 with its compound EC-18.
EC-18 can resolve inflammation by allowing complete viral clearance while minimizing tissue damage, and it may be able to quickly neutralize SARS-CoV-2 by preventing cytokine storm or acute respiratory distress syndrome, according to the company.
Now the company is seeking appropriate partners to develop and commercialize EC-18 worldwide as a potential treatment for COVID-19.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: